Riskpilot← Back to searchSign inGet full accessWELLSPECT AS
ASActiveOrg 927723662Karihaugveien 89, 1086 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 20215 employees
Revenue 2024
NOK 93,4M
+10% vs 2023
EBITDA margin
4.0%
+75% vs 2023
Equity ratio
8.6%
Financial strength
Net profit 2024
NOK -4,3M
+21% vs 2023
| Revenue | NOK 93,4M | +10% |
| EBITDA | NOK 3,7M | +75% |
| Net profit | NOK -4,3M | +21% |
| Total assets | NOK 72,4M | -2% |
| Equity | NOK 6,2M | +12% |
| Employees | 5 | — |
Legal name
WELLSPECT AS
Org number
927723662
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14. september 2021
Share capital
NOK 60 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene eller to styremedlemmer i fellesskap.
Company purpose
Handel med medisinsk utstyr til helsesektoren og enhver virksomhet knyttet til dette, inkludert, men ikke begrenset til, salg og distribusjon av medisinsk utstyr til helsesektoren i norge samt å tilby tjenester, informasjon og undervisning til kunder. Selskapet kan også være interessert i andre selskaper ved tegning av aksjer eller på annen måte.
Address
Karihaugveien 89, 1086 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 48 345 | 84 862 | 93 448 |
| Staff expenses | −3 405 | −7 689 | −6 247 |
| EBITDA | 6 780 | 2 127 | 3 729 |
| Depreciation & amort. | −4 720 | −8 153 | −8 049 |
| EBIT | 2 059 | −6 026 | −4 321 |
| Net financials | −736 | −981 | −1 209 |
| Profit before tax | 1 324 | −7 007 | −5 530 |
| Tax | 298 | −1 529 | −1 200 |
| Net profit | 1 025 | −5 478 | −4 330 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 65 674 | 74 005 | 72 412 |
| Equity | 11 055 | 5 577 | 6 248 |
| Long-term debt | 40 932 | 40 367 | 39 600 |
| Short-term debt | 13 686 | 28 060 | 26 564 |
| Total debt | 54 618 | 68 427 | 66 164 |
EBITDA margin
4.0%
This company
15.8%
Market median
-75% vs market
20222024
Equity ratio
8.6%
This company
38.2%
Market median
-77% vs market
20222024
Return on equity
-69.3%
This company
18.4%
Market median
-477% vs market
20222024
Net profit margin
-4.6%
This company
8.1%
Market median
-157% vs market
20222024
Asset turnover
1.29×
This company
1.12×
Market median
+15% vs market
20222024
Debt / equity
10.59×
This company
0.62×
Market median
-1608% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JA Contact Person | Contact Person | 2024 |
| Former (2) | ||
GØ Contact Person | Contact Person | 2021 – 2024 |
CS Contact Person | Contact Person | 2021 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2024 | |
| Board of Directors | 2024 | |
| Board of Directors | 2022 | |
| Former (3) | ||
| Chairman | 2022 – 2024 | |
| Board of Directors | 2022 – 2024 | |
| Chairman | 2021 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Wellspect Ab | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of WELLSPECT AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jørgen Aasen | Contact Person | 0 companies |
| Guri Ørsal Brandvold | Contact Person | 0 companies |
| Christine Suat Bee Tan Lauten | Contact Person | 0 companies |
| Christopher Francis Schlenk | Chairman | 0 companies |
| Svenn Poulsen | Chairman | 0 companies |
| Jörg Franz Nosek | Board of Directors | 0 companies |
| Jimmy Emil Peder Pedersen | Board of Directors | 0 companies |
| Trond Henning Øvrebø | Chairman | 0 companies |
| Carl Henric Olson | Board of Directors | 0 companies |